Connect with us

Science

Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.
The post Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket…

Published

on

3 Top Health Care Stocks To Watch In December 2021

As the broader stock market looks to end this rollercoaster ride of a week in the green, one fact remains. Namely, the Omicron Covid variant is the latest hurdle in the fight against the pandemic and health care stocks are once again in focus. Accordingly, this would be the case as more alarming updates continue to roll in. As of today, the World Health Organization (WHO) has detected this latest variant of concern in 38 countries worldwide.

Shedding some light on the overall situation now is WHO Covid technical lead Maria Van Kerkhove. To highlight, Van Kerkhove said, “There is a suggestion that there is increased transmissibility, what we need to understand is if it’s more or less transmissible compared to Delta”. While all this remains to be seen, some companies are already establishing early countermeasures. Notably, Alphabet (NASDAQ: GOOGL) subsidiary Google is one such company. As of yesterday, Google is scrapping its plans for a return to physical offices on January 10. Moreover, the tech giant is also adapting its search engine to better serve users’ health care needs. According to a recent blog post, Google Search now helps users find doctors and health care providers matching their insurance and language preferences.

For those looking to directly invest in companies fighting this battle on the frontlines, there are also several options. Among the most notable names would be BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE), the titular Covid vaccine duo. In fact, BioNTech CEO Ugur Shin provided a positive update regarding the company’s Omicron variant response. Sahin notes that the firm can re-design its vaccine to better deal with the variant should it be necessary. On that note, here are three health care stocks gaining traction in the stock market today.

Top Health Care Stocks To Watch Right Now

Longeveron Inc.

Longeveron is a clinical-stage biotech company that develops cellular therapies for aging-related and life-threatening conditions. Its lead investigational product is Lomecel-B, which is derived from medicinal signaling cells (MSC). Accordingly, it believes that by using the same cells that promote tissue repair and organ maintenance, it can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. As it stands, LGVN stock currently trades at $22.07 as of 1:13 p.m. ET and is up by over 22% on today’s opening bell.

LGVN stock

Investors are likely responding to news that the FDA has granted orphan designation to Lomecel-B, as a treatment of Hypoplastic Left Heart Syndrome. Also, orphan drug designation gives companies researching cures for rare diseases a seven-year window of tax reductions and the exclusive right to develop a cure for a specific condition. This builds on the incredible momentum that LGVN stock has enjoyed in the past month alone, gaining by over 480%.

Furthermore, the company announced that it has entered into a sponsored clinical research agreement with the National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital in Japan. Together, they will explore the safety and efficacy of Lomocel-B on aging frailty patients. “We are excited to embark on this collaboration with the NCGG, one of the top advanced and specialized medical research centers in Japan, and Juntendo University Hospital,” said Geoff Green, Chief Executive Officer at Longeveron. “We believe our work could be especially impactful in Japan, which has one of the oldest and fastest aging populations in the world, and where early identification and intervention of frailty is a priority,” continued Mr. Green. Should you invest in LGVN stock right now?

[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist

Merck & Co Inc.

Following that, we have Merck, a health care company that has brought many life-changing medicines and vaccines for many of the world’s most challenging diseases. Today, it continues to be at the forefront of research to prevent and treat diseases that threaten the globe. Hence, this would include the current Covid pandemic. MRK stock currently trades at $72.87 as of 1:13 p.m. ET.

biotech stocks (MRK stock)

On December 1, 2021, the company announced that the FDA has accepted for priority review, a supplemental Biologics License Application (sBLA) for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age. Furthermore, the sBLA is supported by results from Phase 2 and Phase 3 clinical studies in pediatric populations. Also, invasive pneumococcal disease can cause serious and potentially life-threatening infections in infants and children. Children under the age of 2 are particularly vulnerable to pneumococcal infection, and the incidence of invasive pneumococcal disease remains highest in the first year of life.

Earlier in the week, Merck also announced a positive FDA advisory committee vote for its investigational oral antiviral molnupiravir for the treatment of mild to moderate Covid in high-risk adults. The positive outcome of the committee follows a comprehensive review of molnupiravir demonstrating a significant reduction in hospitalizations and death. This comes in a time where the Omicron variant could potentially bring about a new wave of cases across the globe. Given this piece of information, is MRK stock a buy today?

[Read More] Best Growth Stocks To Buy? 4 E-Commerce Stocks To Watch

GlaxoSmithKline

Last but not least, we will be taking a look at GlaxoSmithKline, or GSK for short. By and large, the U.K.-based firm is a titan in the global pharmaceuticals industry. As you can imagine, the company boasts a robust portfolio of products. All of which GSK markets via its pharmaceuticals, vaccines, and consumer health care divisions. To point out, GSK stock now trades at $41.30 as of 1:13 p.m. ET. Among the company’s key areas of focus now would be its Covid antibody cocktail, sotrovimab. Through a partnership with Vir Biotechnology (NASDAQ: VIR), GSK seems to be breaking new ground in the fight against Covid.

coronavirus stocks to buy sell Capricor Therapeutics (CAPR stock)

Just this week, the company provided several key updates regarding sotrovimab. For starters, the Covid treatment is reportedly effective against key mutations in the Omicron variant. While this is according to preclinical data, it is a welcomed piece of news from the company. Subsequently, the treatment was approved by the U.K. Medicine and Healthcare products Regulatory Agency (MHRA).

If we take a deeper look into the data, the current success seen in GSK’s work is not unwarranted. According to CEO George Scangos, clinical data demonstrates a “79% reduction in hospitalizations for more than 24 hours or death in non-hospitalized patients”. Moving forward, Scangos adds that GSK is eager to provide sotrovimab to the NHS among other global health care divisions. With GSK seemingly firing on all cylinders now, would you consider GSK stock worth looking out for?

The post Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Spread & Containment

Easyjet share price down 3% as pandemic losses hit £2.2 billion

The EasyJet share price shed over 3% today to give up a chunk of…
The post Easyjet share price down 3% as pandemic losses hit £2.2 billion first appeared on Trading and Investment News.

Published

on

The EasyJet share price shed over 3% today to give up a chunk of the gains the budget airline had made earlier in the week. The new slide came after it announced a £213 loss for the last quarter of the year covering the Christmas period, taking losses for the Covid-19 pandemic period to £2.2 billion. The airline also told investors it is still burning through £150 million in cash every month as it struggles to build capacity back up.

The short-haul airline that makes most of its income shuttling holidaymakers and business travellers around Europe said it is still only operating at around half of its pre-pandemic capacity. However, it is hopeful that pent-up demand and an end to travel restrictions mean it will return to pre-pandemic levels by summer and enjoy much brisker trade than of late over the Easter and spring period.

easy jet plc

But before then the airline company will again have to absorb deep losses over the current quarter, which is traditionally its weakest of the year. Even a strong summer period, think most analysts, will be insufficient to see the company return to profit this year. EasyJet’s value is still less than half of what it was in February 2020 before the coronavirus-induced market sell-off that hit later that month and saw markets dive into March before starting to recover. The share prices of rival budget airlines Ryanair and WizzAir have recovered much more strongly in comparison to EasyJet’s and are now close to their pre-pandemic levels. There have been concerns around whether EasyJet could survive the pandemic but investors contributed £1.2 billion last autumn to bolster its balance sheet.

The EasyJet share price is closing the week at around £6.15 compared to over £15 before the pandemic. However, there is now hope the worst may be behind the airline and it can begin its, potentially long, journey back to health. Chief executive John Lundgren attempted to soften the announcement of another hefty loss with a bullish statement on where things go from here for his company:

“Booking volumes jumped in the UK following the welcome reduction of travel restrictions announced on January 5, which have been sustained and given a further boost from the UK government’s decision this week to remove all testing requirements.”

“We believe testing for travel across our network should soon become a thing of the past. We see a strong summer ahead, with pent-up demand that will see easyJet returning to near-2019 levels of capacity, with UK beach and leisure routes performing particularly well.”

For now, however, forward guidance for the immediate quarter remains cautious with the company admitting it has fallen short of its expectations to be at 80% capacity by this quarter, sitting at just 67%. However, with most analysts confident the company will eventually return to strength, and profit in the 2022-23 financial year, EasyJet shares could offer a good buying opportunity at current levels.

The post Easyjet share price down 3% as pandemic losses hit £2.2 billion first appeared on Trading and Investment News.

Read More

Continue Reading

Spread & Containment

Authoritarian Madness: The Slippery Slope From Lockdowns To Concentration Camps

Authoritarian Madness: The Slippery Slope From Lockdowns To Concentration Camps

Authored by John W. Whitehead & Nisha Whitehead via The Rutherford Institute,

“All the Dachaus must remain standing. The Dachaus, the Belsens, the Buchenwal

Published

on

Authoritarian Madness: The Slippery Slope From Lockdowns To Concentration Camps

Authored by John W. Whitehead & Nisha Whitehead via The Rutherford Institute,

“All the Dachaus must remain standing. The Dachaus, the Belsens, the Buchenwald, the Auschwitzes—all of them. They must remain standing because they are a monument to a moment in time when some men decided to turn the Earth into a graveyard. Into it they shoveled all of their reason, their logic, their knowledge, but worst of all, their conscience. And the moment we forget this, the moment we cease to be haunted by its remembrance, then we become the gravediggers.”

- Rod Serling, Deaths-Head Revisited

In the politically charged, polarizing tug-of-war that is the debate over COVID-19, we find ourselves buffeted by fear over a viral pandemic that continues to wreak havoc with lives and the economy, threats of vaccine mandates and financial penalties for noncompliance, and discord over how to legislate the public good without sacrificing individual liberty.

The discord is getting more discordant by the day.

Just recently, for instance, the Salt Lake Tribune Editorial Board suggested that government officials should mandate mass vaccinations and deploy the National Guard “to ensure that people without proof of vaccination would not be allowed, well, anywhere.”

In other words, lock up the unvaccinated and use the military to determine who gets to be “free.”

These tactics have been used before.

This is why significant numbers of people are worried: because this is the slippery slope that starts with well-meaning intentions for the greater good and ends with tyrannical abuses no one should tolerate.

For a glimpse at what the future might look like if such a policy were to be enforced, look beyond America’s borders.

In Italy, the unvaccinated are banned from restaurants, bars and public transportation, and could face suspensions from work and monthly fines. Similarly, France will ban the unvaccinated from most public venues.

In Austria, anyone who has not complied with the vaccine mandate could face fines up to $4100. Police will be authorized to carry out routine checks and demand proof of vaccination, with penalties of as much as $685 for failure to do so.

In China, which has adopted a zero tolerance, “zero COVID” strategy, whole cities—some with populations in the tens of millions—are being forced into home lockdowns for weeks on end, resulting in mass shortages of food and household supplies. Reports have surfaced of residents “trading cigarettes for cabbage, dishwashing liquid for apples and sanitary pads for a small pile of vegetables. One resident traded a Nintendo Switch console for a packet of instant noodles and two steamed buns.”

For those unfortunate enough to contract COVID-19, China has constructed “quarantine camps” throughout the country: massive complexes boasting thousands of small, metal boxes containing little more than a bed and a toilet. Detainees—including children, pregnant women and the elderly— were reportedly ordered to leave their homes in the middle of the night, transported to the quarantine camps in buses and held in isolation.

If this last scenario sounds chillingly familiar, it should.

Eighty years ago, another authoritarian regime established more than 44,000 quarantine camps for those perceived as “enemies of the state”: racially inferior, politically unacceptable or simply noncompliant.

While the majority of those imprisoned in the Nazi concentration camps, forced labor camps, incarceration sites and ghettos were Jews, there were also Polish nationals, gypsies, Russians, political dissidents, resistance fighters, Jehovah’s Witnesses, and homosexuals.

Culturally, we have become so fixated on the mass murders of Jewish prisoners by the Nazis that we overlook the fact that the purpose of these concentration camps were initially intended to “incarcerate and intimidate the leaders of political, social, and cultural movements that the Nazis perceived to be a threat to the survival of the regime.”

As the U.S. Holocaust Memorial Museum explains:

“Most prisoners in the early concentration camps were political prisoners—German Communists, Socialists, Social Democrats—as well as Roma (Gypsies), Jehovah's Witnesses, homosexuals, and persons accused of ‘asocial’ or socially deviant behavior. Many of these sites were called concentration camps. The term concentration camp refers to a camp in which people are detained or confined, usually under harsh conditions and without regard to legal norms of arrest and imprisonment that are acceptable in a constitutional democracy.”

How do you get from there to here, from Auschwitz concentration camps to COVID quarantine centers?

Connect the dots.

You don’t have to be unvaccinated or a conspiracy theorist or even anti-government to be worried about what lies ahead. You just have to recognize the truth in the warning: power corrupts, and absolute power corrupts absolutely.

This is not about COVID-19. Nor is it about politics, populist movements, or any particular country.

This is about what happens when good, generally decent people—distracted by manufactured crises, polarizing politics, and fighting that divides the populace into warring “us vs. them” camps—fail to take note of the looming danger that threatens to wipe freedom from the map and place us all in chains.

It’s about what happens when any government is empowered to adopt a comply-or-suffer-the-consequences mindset that is enforced through mandates, lockdowns, penalties, detention centers, martial law, and a disregard for the rights of the individual.

The slippery slope begins in just this way, with propaganda campaigns about the public good being more important than individual liberty, and it ends with lockdowns and concentration camps.

The danger signs are everywhere.

Claudio Ronco, a 66-year-old Orthodox Jew and a specialist in 18th-century music, recognizes the signs. Because of his decision to remain unvaccinated, Ronco is trapped inside his house, unable to move about in public without a digital vaccination card. He can no longer board a plane, check into a hotel, eat at a restaurant or get a coffee at a bar. He has been ostracized by friends, shut out of public life, and will soon face monthly fines for insisting on his right to bodily integrity and individual freedom.

For all intents and purposes, Ronco has become an undesirable in the eyes of the government, forced into isolation so he doesn’t risk contaminating the rest of the populace.

This is the slippery slope: a government empowered to restrict movements, limit individual liberty, and isolate “undesirables” to prevent the spread of a disease is a government that has the power to lockdown a country, label whole segments of the population a danger to national security, and force those undesirables—a.k.a. extremists, dissidents, troublemakers, etc.—into isolation so they don’t contaminate the rest of the populace.

The world has been down this road before, too.

Others have ignored the warning signs. We cannot afford to do so.

As historian Milton Mayer recounts in his seminal book on Hitler’s rise to power, They Thought They Were Free:

“Most of us did not want to think about fundamental things and never had. There was no need to. Nazism gave us some dreadful, fundamental things to think about—we were decent people‑—and kept us so busy with continuous changes and 'crises' and so fascinated, yes, fascinated, by the machinations of the 'national enemies', without and within, that we had no time to think about these dreadful things that were growing, little by little, all around us.”

The German people chose to ignore the truth and believe the lie.

They were not oblivious to the horrors taking place around them. As historian Robert Gellately points out, “[A]nyone in Nazi Germany who wanted to find out about the Gestapo, the concentration camps, and the campaigns of discrimination and persecutions need only read the newspapers.”

The warning signs were there, blinking incessantly like large neon signs.

“Still,” Gellately writes, “the vast majority voted in favor of Nazism, and in spite of what they could read in the press and hear by word of mouth about the secret police, the concentration camps, official anti-Semitism, and so on. . . . [T]here is no getting away from the fact that at that moment, ‘the vast majority of the German people backed him.’”

Half a century later, the wife of a prominent German historian, neither of whom were members of the Nazi party, opined: “[O]n the whole, everyone felt well. . . . And there were certainly eighty percent who lived productively and positively throughout the time. . . . We also had good years. We had wonderful years.”

In other words, as long as their creature comforts remained undiminished, as long as their bank accounts remained flush, as long as they weren’t being locked up, locked down, discriminated against, persecuted, starved, beaten, shot, stripped, jailed or killed, life was good.

Life is good in America, too, as long as you’re able to keep cocooning yourself in political fantasies that depict a world in which your party is always right and everyone else is wrong, while distracting yourself with bread-and-circus entertainment that bears no resemblance to reality.

Indeed, life in America may be good for the privileged few who aren’t being locked up, locked down, discriminated against, persecuted, starved, beaten, shot, stripped, jailed or killed, but it’s getting worse by the day for the rest of us.

Which brings me back to the present crisis: COVID-19 is not the Holocaust, and those who advocate vaccine mandates, lockdowns and quarantine camps are not Hitler, but this still has the makings of a slippery slope.

The means do not justify the ends: we must find other ways of fighting a pandemic without resorting to mandates and lockdowns and concentration camps. To do otherwise is to lay the groundwork for another authoritarian monster to rise up and wreak havoc.

If we do not want to repeat the past, then we must learn from past mistakes.

January 27 marks Remembrance Day, the anniversary of the liberation of Auschwitz-Birkenau, a day for remembering those who died at the hands of Hitler’s henchmen and those who survived the horrors of the Nazi concentration camps.

Yet remembering is not enough. We can do better. We must do better.

As I make clear in my book Battlefield America: The War on the American People and in its fictional counterpart The Erik Blair Diaries, the world is teetering on the edge of authoritarian madness.

All it will take is one solid push for tyranny to prevail.

Tyler Durden Fri, 01/28/2022 - 23:40

Read More

Continue Reading

Spread & Containment

Eli Lilly says FDA could deny expanded use of arthritis drug for eczema

Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.

Published

on

Eli Lilly says FDA could deny expanded use of arthritis drug for eczema

(Reuters) – Eli Lilly and Co (LLY.N) said on Friday it expects the U.S. Food and Drug Administration to decline the approval of expanded use of its rheumatoid arthritis drug as a treatment for adults with moderate-to-severe eczema.

“At this point, the company does not have alignment with the FDA on the indicated population,” the drugmaker said.

Olumiant, discovered by Incyte Corp (INCY.O) and licensed to Lilly, belongs to a class of drugs called JAK inhibitors, which came under regulatory scrutiny after Pfizer’s (PFE.N) arthritis drug Xeljanz showed an increased risk of serious heart-related problems and cancer in a February trial. read more

The path to approval for the drug has been arduous, with the FDA extending its review timeline repeatedly.

AbbVie’s (ABBV.N) rival eczema drug, Rinvoq, also faced similar regulatory hurdles before being finally approved by the FDA earlier this month, as well as Pfizer’s Cibinqo. read more

“While not specified by the company, we wonder if the FDA may be looking to limit the use of the product (Olumiant) to an even smaller subset of patients than what Rinvoq and Cibinqo were approved for,” Mizuho analyst Vamil Divan said in a client note.

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo

Lilly also said it has decided to discontinue its program for testing use of Olumiant in autoimmune disease lupus, based on early results from two late-stage trials.

The decision would adversely affect Lilly which continues to bet on upcoming regulatory decisions on the drug for treating COVID-19 for certain hospitalized patients and severe alopecia areata, a type of hair loss.

In the United States, the drug is already authorized for emergency use in hospitalized adults with COVID-19 and children aged two or older requiring supplemental oxygen or mechanical ventilation. Lilly awaits Olumiant’s full approval in certain hospitalized COVID-19 patients, with an anticipated regulatory action in the second quarter.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri and Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.

Read More

Continue Reading

Trending